Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

On October 14, Li Peng, Corporate Senior Vice President and President of ICT Sales & Service of Huawei, gave his speech at Huawei GITEX 2024, titled 'Thr ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Exploring innovative therapies and market trends in lupus nephritis treatment, highlighting advancements in patient care and emerging drug developments.

According to Research by , Type 1 Diabetes Market Growth is Driven by Innovations in Insulin Delivery Systems, Continuous Glucose Monitoring, and Stem Cell TherapiesPune, Oct. 14, 2024 (GLOBE NEWSWIRE ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.